ArticlePloS one2016
Poor Cervical Cancer Screening Attendance and False Negatives. A Call for Organized Screening.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Increasing Cervical Cancer Screening Coverage: A Randomised, Community-Based Clinical Trial.PloS one · 2017Trial
- HPV-related cancer prevention in Spain: progress and remaining challenges in vaccination, screening, and surveillance.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- SPEACx: a screening pathway-based evaluation and audit framework of cervical cancer diagnostic routes in a population-based programme.Archives of public health = Archives belges de sante publique · 2026Article
- Integrated Cervical Self-Sampling for Cytology, High-Risk Human Papillomavirus, and Sexually Transmitted Infection Testing: A Prospective Study.Diagnostics (Basel, Switzerland) · 2026Article
- Evaluation of the Outcomes of Patients Undergoing Colposcopy for High-Risk Human Papillomavirus Positivity and/or Abnormal Cervical Cytology.Diagnostics (Basel, Switzerland) · 2026Article
- Analysis of the differences between HPV-independent and HPV-related cervical adenocarcinoma.Frontiers in oncology · 2025Article
- Article
- Performance of a vaginal self-collection device versus clinician collected cervical samples for the detection of high-risk human papillomavirus.Preventive medicine reports · 2024Article
- Colposcopy Value in Young Child-bearing Women: Is New Recommendations Necessary?Advanced biomedical research · 2024Article
- A real-world research of cervical cancer screening in patients diagnosed with cervical cancer by loop electrosurgical excision procedure.Gynecology and pelvic medicine · 2024Article
- Article
- Could HPV Type 33 Be More Risky Than We Thought?International journal of surgical pathology · 2023Article
- Trends and Determinants in Uptake of Cervical Cancer Screening in Spain: An Analysis of National Surveys from 2017 and 2020.Cancers · 2022Article
- Clinicopathological features and outcomes in gastric-type of HPV-independent endocervical adenocarcinomas.BMC cancer · 2021Article
- Sample Adequacy Control (SAC) Lowers False Negatives and Increases the Quality of Screening: Introduction of "Non-Competitive" SAC for qPCR Assays.Diagnostics (Basel, Switzerland) · 2021Article
- Comparison of Cervical Levels of Interleukins-6 and -8 in Patients with and without Cervical Intraepithelial Neoplasia.Asian Pacific journal of cancer prevention : APJCP · 2021Article
- HPV Infection Significantly Accelerates Glycogen Metabolism in Cervical Cells with Large Nuclei: Raman Microscopic Study with Subcellular Resolution.International journal of molecular sciences · 2020Article
- Article
- Plasma levels of M-CSF and VEGF in laboratory diagnostics and differentiation of selected histological types of cervical cancers.BMC cancer · 2019Article
- Comparison of Colposcopic Biopsy Results of Patients Who have Cytomorphological Normal but HPV 16-18 or Other High-Risk HPV Subtypes PositiveAsian Pacific journal of cancer prevention : APJCP · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe objective of this study was to describe prior negative screening history and symptoms around the time of diagnosis of incident cervical cancer (CC) cases diagnosed between 2000 and 2010 within the Asturias public health system.
methodsRecords from 374 women diagnosed with CC between 2000 and 2010 from all public hospitals in Asturias were retrieved. Clinical information, FIGO stage and all previous cytological data were extracted from clinical and histopathological records. Proportional differences were assessed using chi-square tests. Logistic regression analysis was used to estimate odds ratios (OR) and 95% confidence intervals (CI). Inter-observer agreement in cytology was checked by comparing concordance values using k-statistics.
resultsNo prior screening history was recorded in 60.7% of CC cases and its absence increased with age and advanced stage. Advanced stage (e.g., ≥ II) at diagnosis was associated with age (>50 years) and adenocarcinoma (ADC) compared to younger women and those with a squamous cell carcinoma (SCC). False negative smears were identified in 27.1% of women with CC (ADC 52.6% vs. SCC 16.2%, p<0.05).
conclusionsAbsence of prior screening history was common among CC cases. Organized actions to reduce "under screening" and the use of highly sensitive HPV-based tests could be useful strategies in reducing the burden of CC in Asturias.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.